Topics

Multimodal Notch Signaling Mediates Development And Disease

Intercellular Communication & Diseases Multiprotein Complexes and Disease Chronic Inflammation Cancer Immunotherapy

Notch is an evolutionarily conserved, contact-dependent signaling system that controls cell-fate decisions, tissue patterning, stem-cell maintenance, and adult homeostasis. Its study began with Drosophila developmental mutants and expanded after cloning of receptors, ligands, proteases, and nuclear effectors. The term multimodal describes how one compact pathway produces different outputs through ligand identity, signal strength and duration, cis and trans interactions, cell geometry, receptor trafficking, chromatin context, and cooperation with other pathways. This context dependence explains why Notch can promote growth in one tissue, drive differentiation or death in another, and function as an oncogene or tumor suppressor[1][2].

A membrane-bound Delta-like or Jagged ligand on one cell binds a Notch receptor on an adjacent cell. Mechanical pulling exposes a proteolytic site, ADAM proteases release the ectodomain, and gamma-secretase liberates the Notch intracellular domain. NICD enters the nucleus, binds RBPJ, displaces repressors, and recruits MAML-containing coactivator complexes to activate target genes such as HES and HEY family members. Glycosylation, endocytosis, receptor turnover, ligand competition, and cis-inhibition tune activation before cleavage. Oscillatory or sustained target-gene expression can encode different developmental decisions, while cross-talk with Wnt, TGF-beta, hypoxia, and inflammatory signaling expands the output space[1][2].

Disease applications include T-cell acute lymphoblastic leukemia, solid tumors, vascular malformations, congenital syndromes, fibrosis, and disorders of tissue regeneration. Activating NOTCH1 mutations are major drivers in T-cell leukemia, supporting gamma-secretase inhibition and more selective approaches against receptors, ligands, or transcriptional complexes. In solid tumors, treatment must respect lineage and stage because blocking Notch can suppress tumor growth yet damage intestinal or vascular homeostasis, and in some contexts Notch restrains malignancy. Mechanistic studies use organoids, lineage tracing, live reporters, and ligand-patterned surfaces to measure dose, timing, and neighborhood effects rather than treating pathway activity as simply on or off[1][2][3].

Major gaps concern quantitative decoding and therapeutic selectivity. Common readouts average cells and miss pulses, cell-contact history, and receptor-specific outputs. Future studies should combine endogenous live reporters, spatial transcriptomics, proteomics, and controlled ligand presentation with mathematical models that predict fate from signal dynamics. Perturbations should separate cleavage, NICD stability, enhancer occupancy, and target-network feedback. Clinical biomarkers must identify whether a tumor depends on a particular receptor-ligand pair and whether inhibition will affect normal stem-cell compartments. Antibodies, ligand traps, degraders, and transcription-complex inhibitors may narrow the therapeutic window, but they require direct comparison with gamma-secretase blockade. Multimodal Notch biology is clinically useful only when tissue context, dose, timing, and cellular topology are specified Experimental comparisons should match ligand density, receptor abundance, and contact duration. Soluble ligands or overexpressed NICD bypass mechanical and trafficking steps and cannot model every physiological interaction. Allele-specific studies can determine whether a mutation changes cleavage, degradation, transcriptional complex assembly, or target selection. In treatment studies, serial measurement of canonical targets and lineage state can expose adaptation and pathway reactivation. Combining Notch inhibition with chemotherapy or immunotherapy should follow demonstrated resistance mechanisms rather than pathway expression alone. These controls preserve the central insight of the field: a receptor can deliver different biological information because the receiving network and contact history shape the response[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family   Ephrin Receptor   PDGFR  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
317
HY-N0565B Doxycycline hyclate
Doxycycline hyclate, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline hyclate shows antibacterial activity and anti-cancer cell proliferation activity. Doxycycline hyclate can be used to construct gene expression regulation models.
Antibiotic   MMP   Bacterial   Parasite  
Breast Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Staphylococcus Aureus Infection   Chlamydia Infection   Lung Fibrosis  
197
HY-N0565 Doxycycline
Doxycycline, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline shows antibacterial activity and anti-cancer cell proliferation activity.
MMP   Bacterial   Antibiotic   Parasite  
Breast Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Staphylococcus Aureus Infection   Chlamydia Infection   Lung Fibrosis  
197
HY-13027 DAPT
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.
Organoid   γ-secretase   Amyloid-β   Autophagy   Notch   Apoptosis  
Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Digestive System Inflammation   Alzheimer's Disease   Rheumatoid Arthritis  
174
HY-12270 T-5224
T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription.
AP-1   MMP  
Pancreatic Cancer   Depression   Pain   Lung Fibrosis  
109
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-L017 Stem Cell Signaling Compound Library
Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy. MCE owns a unique collection of 2,931 compounds that can be used for stem cell regulatory and signaling pathway research.

Signaling Pathway Targeting Libraries

86
HY-L020 Wnt/Hedgehog/Notch Compound Library
The developmental proteins Hedgehog, Notch and Wnt are key regulators of cell fate, proliferation, migration and differentiation in several tissues. Their related signaling pathways are frequently activated in tumors, and particularly in the rare subpopulation of cancer stem cells. The Wnt signaling pathway is a conserved pathway in animals. Deregulated Wnt signaling has catastrophic consequences for the developing embryo and it is now well appreciated that defective Wnt signaling is a causative factor for a number of pleiotropic human pathologies, including cancer. Hedgehog signaling pathway is linked to tumorigenesis and is aberrantly activated in a variety of cancers. The Notch signaling pathway is a highly conserved cell signaling system present in most animals. It plays an important role in cell-cell communication, and further regulates embryonic development. MCE designs a unique collection of 654 Wnt/Hedgehog/Notch signaling pathway-related small molecules. Wnt/Hedgehog/Notch Compound Library serves as a useful tool for stem cell research and anti-cancer drug screening.

Signaling Pathway Targeting Libraries

86
HY-L013 Neuronal Signaling Compound Library
Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders. MCE designs a unique collection of 3,961 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

Signaling Pathway Targeting Libraries

84
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L083 Anti-Cancer Metabolism Compound Library
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth. MCE provides a unique collection of 3,806 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Signaling Pathway Targeting Libraries

84
HY-L188 Anti-Brain Cancer Compound Library
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
84
HY-L074 Anti-Breast Cancer Compound Library
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Disease Focused Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L103 Anti-Colorectal Cancer Compound Library
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 2,653 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L135 Cancer Stem Cells Compound Library
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 3,540 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Compound Characteristic Classified Libraries

83
HY-L173 Anti-Ovarian Cancer Compound Library
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 2,967 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Disease Focused Libraries

83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-10585B Valproic acid sodium (2:1)
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
HDAC   Autophagy   Mitophagy   HIV   Notch   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
70
HY-10585A Valproic acid sodium
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
Organoid   HDAC   Autophagy   Mitophagy   HIV   Notch   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
70
HY-10585 Valproic acid
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
Organoid   HDAC   Autophagy   Mitophagy   HIV   Notch   Apoptosis   Endogenous Metabolite  
Infection   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Respiratory Disease   Small Cell Lung Cancer  
70
HY-15768 Ilomastat
Ilomastat (GM6001) is a potent and broad spectrum matrix metalloprotease (MMP) inhibitor, inhibits MMPs (IC50s, 1.5 nM for MMP-1; 1.1 nM for MMP-2; 1.9 nM for MMP-3; 0.5 nM for MMP-9), with a Ki of 0.4 nM for human skin fibroblast collagenase (MMP-1).
MMP  
Pancreatic Cancer   Pain   Lung Fibrosis   Rheumatoid Arthritis  
67
HY-50752 LY-411575
LY-411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with an IC50 of 0.39 nM.
Organoid   γ-secretase   Notch   Apoptosis  
Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Neurodegenerative Disease   Digestive System Inflammation   Rheumatoid Arthritis  
29
HY-11102 RO4929097
RO4929097 is an orally active γ secretase inhibitor with an IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively.
γ-secretase   Notch  
Respiratory Disease   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Viral Infection   Neurodegenerative Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Rheumatoid Arthritis  
21
HY-E70005A Collagenase, Type I
Collagenase, Type I is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type I breaks down collagens 1, 3, 7, 8, 10, gelatin, proteoglycans, aggrecan.
MMP  
21
HY-E70005D Collagenase IV, Clostridium histolytica
Collagenase, Type IV (EC 3.4.24.3) is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type IV degrades type IV collagen and type VII collagen, the main components of the basement membrane, and can also decompose basement matrix and elastin.
MMP  
21
HY-B0239 Chloramphenicol
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research.

Source: Streptomyces venezuelae

Antibiotic   Bacterial   HIF/HIF Prolyl-Hydroxylase   VEGFR   Autophagy   Apoptosis   Beclin1   JNK   Akt   MMP  
Infection   Respiratory Disease   Non-Small Cell Lung Cancer  
20
HY-P1846A Jagged-1 (188-204) TFA
Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
Notch  
Cancer  
19
HY-15096 MKT-077
MKT-077 (FJ-776), a highly water-soluble mitochondrial dye, has significant antitumor activity. MKT-077 exhibits low cytotoxicity, and inhibits broad-spectrum human cancer cell lines (colon cancer, breast cancer, pancreatic cancer). MKT-077 inhibits the growth of tumor in nude mice enograft tumor model. Ex/Em=488/543 nm.
Fluorescent Dye   HSP  
Breast Cancer  
18
HY-14176 Compound E
Compound E is a γ-secretase inhibitor. Compound E blocks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC50s of 0.24, 0.37, 0.32 nM, respectively.
γ-secretase  
Cancer  
18
HY-N0133 Tangeretin
Tangeretin (Tangeritin), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and is a Notch-1 inhibitor.
Notch   Apoptosis  
Neurological, Eye or Ear Disease   Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Digestive System Inflammation   Rheumatoid Arthritis  
16
HY-15185 Nirogacestat
Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers.
γ-secretase   Apoptosis  
Breast Cancer   Pancreatic Cancer   Neurodegenerative Disease   Multiple Myeloma  
16
HY-E70005B Collagenase, Type II
Collagenase, Type II is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type II breaksdown collagens1, 3, 5, 7, 8, 10, fibronectin, gelatin, aggrecann.
MMP  
16
HY-10974 MK-0752
MK-0752 is a potent, orally active and specific γ-secretase inhibitor, showing dose-dependent reduction of Aβ40 with an IC50 of 5 nM in human SH-SY5Y cells. MK-0752 crosses the blood-brain barrier. MK-0752 reduces newly generated CNS Aβ in vivo.
γ-secretase  
Pancreatic Cancer   Neurodegenerative Disease  
14
HY-10009 Semagacestat
Semagacestat is a γ-secretase inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC50s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC50 of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease.
γ-secretase   Amyloid-β   Notch  
Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Rheumatoid Arthritis  
12
HY-N0711 Carvacrol
Carvacrol is an orally active and blood-brain barrier-permeable monoterpenic phenol that can be extract from an abundant number of aromatic plants, including thyme and oregano, possessing antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, hepatoprotective, spasmolytic, and vasorelaxant properties. Carvacrol also causes cell cycle arrest in G0/G1, downregulates Notch-1, and Jagged-1, and induces apoptosis. Carvacrol is used in low concentrations as a food flavoring ingredient and preservative, as well as a fragrance ingredient in cosmetic formulations.
Environmental Pollutants   Notch   Endogenous Metabolite   Bacterial   Apoptosis   Fungal  
Neurological, Eye or Ear Disease   Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Bacterial Infection   Fungal Infection   Digestive System Inflammation   Rheumatoid Arthritis  
11
HY-148905 p-Aminophenylmercuric acetate
p-Aminophenylmercuric acetate is an organomercurial activator of matrix metalloproteinases (MMP). P-Aminophenylmercuric acetate participates in the activation and inhibition of MMP-8 by attacking protein sulfhydryl or inducing cysteine switching reaction. p-Aminophenylmercuric acetate promotes the shedding of betacellulin precursor (pro-BTC). p-Aminophenylmercuric acetate influences the binding of agonists and antagonists to the opiate receptor.
Cathepsin   MMP  
Infection  
11
HY-12449 Crenigacestat
Crenigacestat (LY3039478) is an orally active Notch and γ-secretase inhibitor, with an IC50 of 1 nM in most of the tumor cell lines tested.
Notch   γ-secretase  
Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Neurodegenerative Disease   SARS-CoV-2 Infection   Rheumatoid Arthritis  
8
HY-13526 YO-01027
YO-01027 (Dibenzazepine;DBZ) is a potent γ-secretase inhibitor with IC50 values of 2.92 and 2.64 nM for Notch and APPL cleavage, respectively.
Notch   γ-secretase  
Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Neurodegenerative Disease   Rheumatoid Arthritis  
8
HY-19369 L-685458
L-685458 is a potent transition state analog (TSA) γ-secretase inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC50s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers.
γ-secretase   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease  
6
HY-N0232 Psoralidin
Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties. Psoralidin significantly downregulates NOTCH1 signaling. Psoralidin also greatly induces ROS generation.
COX   Lipoxygenase   Notch   Reactive Oxygen Species (ROS)   Bacterial  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Bacterial Infection   Depression   Rheumatoid Arthritis  
5
HY-12316 20(S)-Hydroxycholesterol
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC50 of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis.
Smo   Endogenous Metabolite  
Cancer   Osteogenic Differentiation  
5
HY-139109 IR-783
IR-783 (ADS 780WS) is a heptamethine cyanine dye. IR-783 induces Mitochondrial membrane potential loss, ATP depletion, mitochondrial permeability transition pore opening, Cytochrome c release and Apoptosis in breast cancer cells. IR-783 promotes the translocation of Drp1 from the cytosol to mitochondria. IR-783 increases the expression of mitochondrial fission proteins such as MFF and Fission-1. IR-783 possesses imaging, cancer-targeting and anticancer properties. IR-783 exerts anticancer effects against breast cancer. IR-783 can be used in breast cancer-related research.
Fluorescent Dye   Apoptosis   Mitochondrial Metabolism   ATP Synthase   Cytochrome P450   Dynamin  
Breast Cancer  
4
HY-P7696 CA125 Protein, Human (HEK293, His)
CA125 is a giant mucin-like glycoprotein expressed by epithelial ovarian neoplasms and cells, which is an antigenic tumor marker. CA125 provides a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. CA125 binds to mesothelin (MSLN) mediates heterotypic cell adhesion, contributing to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium. CA125 is widely used for monitoring with ovarian epithelial cancer. CA125 Protein, Human (HEK293, His) is a recombinant human cancer antigen 125 (CA125) with a His label and is expressed in HEK293 cells.

Species: Human; Source: HEK293

CAR-T Related Proteins CA-125

4
HY-P99575 Tarlatamab
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

Species: Human

Notch  
Inflammation or Immune System Disease   Respiratory Disease   Small Cell Lung Cancer  
3
HY-W008091R 5-Methylcytosine (Standard)
5-Methylcytosine (Standard) is the analytical standard of 5-Methylcytosine (HY-W008091). This product is intended for research and analytical applications. 5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma.
Reference Standards   DNA/RNA Synthesis   Endogenous Metabolite  
Cancer  
2
HY-W008091 5-Methylcytosine
5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma.

Source: prokaryotes and eukaryotes

DNA/RNA Synthesis   Endogenous Metabolite  
Colorectal Cancer   Liver Cancer  
2
HY-10585S3 Valproic acid-d4 sodium
Valproic acid-d4 (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
Isotope-Labeled Compounds   HDAC   Autophagy   Mitophagy   HIV   Notch   Endogenous Metabolite  
1
HY-10585S Valproic acid-d4
Valproic acid-d4 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
HDAC   Autophagy   Mitophagy   HIV   Notch   Endogenous Metabolite  
1
HY-N2830 Agrimonolide
Agrimonolide is a phenethyl isocoumarin compound discovered from Agrimonia pilosa, exhibiting anti-inflammatory, antioxidant, and anticancer activities. Agrimonolide inhibits NF-κB, MAPK, and TLR4-mediated neuroinflammatory signaling, suppresses Notch and JAK2/STAT3 signaling to modulate Th17/Treg balance and maintain the intestinal barrier. Agrimonolide decreases HIF1A expression, inhibits glycolysis, and induces ferroptosis and cell cycle arrest via the mTOR pathway in tumor models, thereby suppressing cancer cell viability, proliferation, and metastasis. Agrimonolide exerts hepatoprotective and anti-fibrotic effects by regulating bile acid transporter expression and reducing hepatic bile acid accumulation. Agrimonolide is used for research on ulcerative colitis, ovarian cancer, non-small cell lung cancer, cholestatic liver injury, and neuroinflammation.
NF-κB   Ferroptosis   MAPKAPK2 (MK2)   Toll-like Receptor (TLR)   Notch   JAK   STAT   HIF/HIF Prolyl-Hydroxylase  
Ovarian Cancer   CNS Infection   Non-Small Cell Lung Cancer   Ulcerative Colitis   Liver Injury  
1
HY-121608 Lumiflavin
Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer.
Fluorescent Dye   Notch  
1
HY-K6105 Human Gastric Cancer Organoid Kit

MCE Human Gastric Cancer Organoid Kit contains Gastric Cancer Organoid Basal Medium A, Gastric Cancer Organoid Supplement B (50×), Gastric Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human gastric cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

1
HY-13526G YO-01027 (GMP)
YO-01027 (Dibenzazepine) (GMP) is YO-01027 (HY-13526) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. YO-01027 is a potent γ-secretase inhibitor.
Notch   γ-secretase  
Cancer  
/
HY-10585AS Valproic acid-d7 sodium
Valproic acid-d7 (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
Isotope-Labeled Compounds   HDAC   Autophagy   Mitophagy   HIV   Notch   Endogenous Metabolite  
/
HY-B2099S Buformin-d9 hydrochloride
Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
Isotope-Labeled Compounds   AMPK  
Metabolic or Endocrine Disease  
/
HY-N17453 (+)-Mornaphthoate E
(+)-Mornaphthoate E is a growth inhibitor that suppresses cancer cell proliferation. It can be used in research on cancers such as lung cancer and breast cancer.
Others  
Breast Cancer   Non-Small Cell Lung Cancer  
/
HY-N17825 Terrestroside A
Terrestroside A is an anticancer agent. Terrestroside A inhibits the growth of various cancer cells in vitro. Terrestroside A can be used for the research of lung cancer, central nervous system cancer and breast cancer.
Others  
Lung Cancer   Breast Cancer  
/
HY-P11624 PP-60
PP-60 is an apoptosis inducer. PP-60 inhibits the proliferation of cancer cells and induces cancer cell apoptosis. PP-60 exerts anti-tumor effects in nude mouse liver tumor models. PP-60 is applicable to research related to cancers such as liver cancer, lung cancer, and prostate cancer.
Apoptosis  
Lung Cancer   Prostate Cancer   Liver Cancer  
/
HY-P3779 Amyloid 17-42
Amyloid 17-42 (Aβ(17-42)) is a major constituent of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, derived by alpha- and gamma-secretase cleavage of the amyloid precursor protein (APP). Amyloid 17-42 can induce neuronal apoptosis via a Fas-like/caspase-8 activation pathway.
Apoptosis  
Neurological, Eye or Ear Disease  
/
HY-P990206 Anti-Mouse Jagged 2 Antibody (HMJ2-1)
Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonal antibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE).

Species: Mouse

Notch   Interleukin Related  
Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
/
HY-P11255 SPDI-48-T1
SPDI-48-T1 is a lysine-stapled peptide. SPDI-48-T1 exhibits discernible binding affinities for MDM2 and MDMX, with Kd values of 396 nM and 456 nM, respectively. SPDI-48-T1 exhibits anticancer activity against breast cancer, colorectal cancer, non-small cell lung cancer, cervical cancer, and malignant melanoma.
MDM-2/p53  
Cancer  
/
HY-N19739 Efrapeptin F
Efrapeptin F is a mitochondrial complex V inhibitor and cytotoxic agent with in vivo antitumor activity. Efrapeptin F induces cell death in glucose-limiting conditions, with preferential cytotoxicity to nutrient-deprived cancer cells under hypoxic conditions. Efrapeptin F can be used for the research of pancreatic cancer, prostate cancer, breast cancer, central nervous system cancer, colon cancer, lung cancer, melanoma, ovarian cancer, kidney cancer, stomach cancer.

Source: Tolypocladium geodes

Mitochondrial Metabolism  
Cancer  
/
HY-D3158 LGP-CL
LGP-CL is a chemiluminescent probe. LGP-CL can be used to evaluate elevated protease levels in both in vitro and in vivo systems, and to distinguish hepatocellular carcinoma cells from normal cells and other cancer cell lines. LGP-CL is applicable to liver cancer-related research.
Fluorescent Dye  
Liver Cancer  
/
HY-N18236 3β-Acetoxyl-atractylenolide I
3β-Acetoxyl-atractylenolide I is a LSD1 inhibitor with an IC50 of 57 μM. 3β-Acetoxyl-atractylenolide I blocks tumor growth, metastasis and invasion. 3β-Acetoxyl-atractylenolide I is used in the research of various cancers including prostate cancer, breast cancer, neuroblastoma, gastric cancer, colon cancer, bladder cancer, esophageal cancer, acute myeloid leukemia and retinoblastoma.
Histone Demethylase  
Breast Cancer   Prostate Cancer   Gastric Cancer   Bladder Cancer   Acute Myeloid Leukemia   Esophageal Cancer  
/
HY-P11658 Anticancer peptoid 1
Anticancer peptoid 1 (Peptoid 1) is a peptoid with antitumor activity. Anticancer peptoid 1 exerts cytotoxicity primarily via plasma membrane damage. Anticancer peptoid 1 exerts cytotoxicity against a broad range of cancer cell lines, including those with multidrug resistance. Anticancer peptoid 1 inhibits tumor growth in a human breast cancer xenotransplantation mouse model without noticeable acute adverse effects. Anticancer peptoid 1 can be used for the research of cancer, such as breast cancer, and prostate cancer.
Others  
Breast Cancer   Prostate Cancer  
/
HY-182259 Montanastatin
Montanastatin is an antitumor agent that can be isolated from the terrestrial actinomycete Streptomyces anulatus. Montanastatin inhibits the growth of various cancer cells. Montanastatin can be used in research related to lymphocytic leukemia, ovarian cancer, brain cancer, renal cancer, lung cancer, colon cancer and melanoma.
Others  
Lung Cancer   Colorectal Cancer   Leukemia/Lymphoma/Myeloma   Melanoma   Ovarian Cancer   Renal Cancer  
/
HY-P11078 LARLLT
LARLLT (D4) is an EGFR-binding peptide. LARLLT has the potential for research of EGFR overexpressing cancers, such as lung, ovarian and colorectal cancer.
EGFR  
Cancer  
/
HY-158498 FA2 glycan (G0F)
FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research.
Biochemical Assay Reagents  
Prostate Cancer  
/
HY-15947G Ravoxertinib (GMP)
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
ERK   c-Myc   Hexokinase   Lactate Dehydrogenase  
Breast Cancer   Ovarian Cancer   Squamous Cell Carcinoma  
/
HY-N21630 Phanginin F
Phanginin F is a cassane-type furanoditerpenoid anticancer agent. Phanginin F can be isolated from the seeds of Caesalpinia sappan Linn. Phanginin F exhibits anticancer activity against ovarian cancer, gastric cancer, and non-small cell lung cancer. Phanginin F can be used in research on ovarian cancer, gastric cancer, and non-small cell lung cancer.
Drug Intermediate  
Gastric Cancer   Ovarian Cancer   Non-Small Cell Lung Cancer  
/
HY-D3182 AldRed 588-A
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Cancer  
/
HY-P991235 FS102
FS102 is a selective Fc fragment with antigen binding (Fcab) that targets HER2 with a KD value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer.

Species: Human

EGFR   Caspase  
Cancer  
/
HY-D3185 AlDeSense AM
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
Fluorescent Dye   Aldehyde Dehydrogenase (ALDH)  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-P992321 BAY-356
BAY-356, a potent TWEAK receptor agonist, is an aglycosylated anti-TWEAK receptor antibody. BAY-356 triggers TWEAKR hyperactivation, activates NFκB and STAT1 pathways, and undergoes TWEAKR-dependent internalization. BAY-356 can be used for the research of colorectal cancer, bladder cancer, non-small cell lung cancer and pancreatic cancer[1][2].

Species: Human

TNF Receptor   NF-κB   STAT  
Colorectal Cancer   Bladder Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer  
/
HY-13673S1 Goserelin-d7
Goserelin-d7 (ICI 118630-d7) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds   Apoptosis   GnRH Receptor  
Cancer   Metabolic or Endocrine Disease  
/
HY-D2062 ATTO 740 NHS ester
ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models.
Fluorescent Dye   Integrin  
Cancer  
/
HY-P4144 Onvitrelin ucalontide
Onvitrelin ucalontide (Phor18-LHRH (338613); EP-100) is a luteinizing hormone-releasing hormone (LHRH) receptor ligand. Onvitrelin ucalontide binds to functional LHRH receptors on cancer cells and mediates targeted cytotoxicity. Onvitrelin ucalontide reduces tumor volume, weight and the number of viable tumor cells in xenograft models. Onvitrelin ucalontide can be used for the research of breast cancer, ovarian cancer and prostate cancer.
GnRH Receptor  
Breast Cancer   Prostate Cancer   Ovarian Cancer  
/
HY-P991980 H2Mab-139
H2Mab-139 (H2Mab-141;H2Mab-19) is an anti-HER2 monoclonal antibody. H2Mab-139 specifically binds to HER2 on various cancer cells. H2Mab-139 can detect HER2 overexpression in colorectal cancer via flow cytometry and immunohistochemical analysis. H2Mab-139 exhibits anti-tumor activity in mouse oral cancer and breast cancer xenografts. H2Mab-139 is applicable to research related to multiple cancers including colon cancer, oral cancer, and breast cancer.

Species: Human

EGFR  
Breast Cancer  
/
HY-10585AG Valproic acid sodium (GMP)
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
Organoid   HDAC   Autophagy   Mitophagy   HIV   Notch   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P992275 Anti-Nicastrin Antibody (A5226A)
Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease.

Species: Human

γ-secretase  
Non-Small Cell Lung Cancer   Acute Lymphoblastic Leukemia   Alzheimer's Disease  
/
HY-N19127 Aspergillusidone E
Aspergillusidone E is an aromatase inhibitor with an aromatase IC50 of 1.0 μM. Aspergillusidone E exhibits cytotoxicity against cancer cells. Aspergillusidone E can be used in research related to various cancers such as breast cancer and liver cancer.

Source: Aspergillus unguis

Cytochrome P450  
Breast Cancer   Liver Cancer  
/
HY-P10789 P160 peptide
The P160 peptide is a breast cancer-targeting peptide that binds to the keratin 1 (KRT1) receptor on breast cancer cells, with a Kd of approximately 1.1 μM, demonstrating significant potential for targeted drug delivery to breast cancer cells. The P160 peptide enhances the cellular uptake and anticancer activity of the pro-apoptotic antimicrobial peptide MccJ25 (microcin J25). The P160 peptide can be used in cancer research.
Microtubule/Tubulin  
/
HY-D3196 AG2
AG2 is a glucose uptake tracer and two-photon fluorescent probe. AG2 is taken up by cells via glucose-specific transport systems, rather than passive diffusion; it preferentially accumulates in cancer cells and colon cancer tissues compared with normal cells and tissues; it mainly localizes to mitochondria, with a small amount also distributed in the cytoplasm and cell membrane. AG2 can be used for colon cancer research.
Fluorescent Dye  
Cancer  
/
HY-B1786S Sulindac sulfide-d3
Sulindac sulfide-d3 is deuterium labeled Sulindac sulfide. Sulindac sulfide is a noncompetitive γ-secretase inhibitor, with an IC50 of 20.2 μM for γ42-secretase activity.
Isotope-Labeled Compounds   γ-secretase  
Neurological, Eye or Ear Disease  
/
HY-E70178 Protein O-Glucosyltransferase 1
Protein O-Glucosyltransferase 1 is a glucosyltransferase. Protein O-Glucosyltransferase 1 modifies Notch signaling by adding glucose to serine residues in Notch.
Glucosylceramide Synthase (GCS)  
/
HY-W742805 Sulindac Sulfone-d6
Sulindac Sulfone-d6 is the deuterium labeled Sulindac sulfone (HY-B1787). Sulindac sulfone is an mTORC1 pathway inhibitor and a metabolite of Sulindac. Sulindac sulfone inhibits colon cancer cell growth and induces cell cycle arrest. Sulindac sulfone is used in cancer research.
Isotope-Labeled Compounds   Drug Metabolite   mTOR  
/
HY-N21702 Hypelodin A
Hypelodin A is a Hypelodin. Hypelodin A can be isolated from H. beanii. Hypelodin A can be used in research on colorectal cancer, breast cancer, and liver cancer.
Drug Intermediate  
Breast Cancer   Colorectal Cancer   Liver Cancer  
/
HY-131492S Δ4-Dafachronic Acid-d3
Δ4-Dafachronic Acid-d3 is deuterium labeled Δ4-Dafachronic acid (HY-131492). Δ4‑Dafachronic acid is an endogenous steroid hormone, an agonist of the DAF‑12 nuclear receptor, and a key ligand for the vitamin D receptor (VDR). Δ4‑Dafachronic acid promotes the active escape developmental trajectory in Austrofundulus limnaeus embryos even under diapause‑inducing conditions. Δ4‑Dafachronic acid is suitable for research on the developmental biology.
Isotope-Labeled Compounds   Endogenous Metabolite   VD/VDR  
Metabolic or Endocrine Disease  
/
HY-P991378 MORAb-066
MORAb-066 is a human monoclonal antibody (mAb) targeting CD142/F3/TF. MORAb-066 can be used in Breast cancer, Colorectal cancer, Non-small cell lung cancer and Pancreatic cancer research.

Species: Human

Transmembrane Glycoprotein  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-14176G Compound E (GMP)
Compound E (GMP) is a GMP-grade Compound E (HY-14176). GMP-grade small molecules can be used as adjuvant reagents in cell therapy. Compound E is a γ-secretase inhibitor. Compound E inhibits β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC50 values ​​of 0.24, 0.37, and 0.32 nM, respectively.
γ-secretase  
Cancer  
/
HY-100187S (Rac)-[6]-Gingerol-13C,d3
(Rac)-[6]-Gingerol-13C,d3 ((±)-[6]-Gingerol-13C,d3) is the deuterium and 13C-labeled (Rac)-[6]-Gingerol (HY-100187). (Rac)-[6]-Gingerol is a natural product. (Rac)-[6]-Gingerol can be isolated from rhizomes of Z. officinale. (Rac)-[6]-Gingerol shows moderate anticancer activity against lung cancer, ovarian cancer, melanoma, and colon cancer.
Isotope-Labeled Compounds   Drug Isomer  
Cancer  
/
HY-P11598 PSMA-N5
PSMA-N5 (Compound 15) is a PSMA ligand with a Ki value of 0.71 nM. PSMA-N5 acts as a PET radiotracer for prostate cancer imaging. PSMA-N5 is applicable to the research of prostate cancer and other related cancers.
PSMA  
Prostate Cancer  
/
HY-16562AS Irinotecan-d5 hydrochloride
Irinotecan-d5 hydrochloride is deuterated labeled Irinotecan hydrochloride (HY-16562A). Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer.
Autophagy   Topoisomerase   Isotope-Labeled Compounds  
/
HY-N18186 Neojiangyouaconitine
Neojiangyouaconitine is a diterpenoid alkaloid cytotoxin isolated from Aconitum soongaricum var. pubescens. Neojiangyouaconitine exhibits cytotoxic activity against human breast cancer, prostate cancer and lung cancer cells, with weak inhibitory effect on HeLa cells. Neojiangyouaconitine has the ability to kill specific tumor cell lines and can be applied to the research on the mechanisms of related cancers such as breast cancer, prostate cancer and lung cancer.
Others  
Lung Cancer   Breast Cancer   Prostate Cancer  
/
HY-P4376B Gamma-Glu-Abu acetate
Gamma-Glu-Abu acetate is a CaSR activator with an EC50 of 0.21 μM (in HEK-293 cells). Gamma-Glu-Abu acetate interacts with the extracellular venus flytrap domain of hCaSR via its N-terminal γ-L-glutamyl residue, the neutral aliphatic side chain of the Abu residue, and the C-terminal carboxylic acid group.
CaSR  
/
HY-P991417 LYN00101
LYN00101 is a human monoclonal antibody (mAb) targeting VEGFA. LYN00101 can be used in Cervical cancer, Colorectal cancer, Gastric cancer and Ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-E70172 Heparan Sulfate 3-O-Sulfotransferase 4
Heparan Sulfate 3-O-Sulfotransferase 4 is a sulfotransferase. Heparan Sulfate 3-O-Sulfotransferase 4 regulates Notch signaling.
Notch  
Neurological, Eye or Ear Disease  
/
HY-E70188 N-Acetylgalactosamine-6-Sulfatase
N-Acetylgalactosamine-6-Sulfatase (GALNS) is a potential general biomarker for multiple malignancies (such as lung cancer, breast cancer, head and neck cancer, etc.). N-Acetylgalactosamine-6-Sulfatase deficiency causes mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. N-Acetylgalactosamine-6-Sulfatase can be used in MPS IVA as well as cancer research.
Biochemical Assay Reagents  
/
HY-15244G Alpelisib (GMP)
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
PI3K   Apoptosis  
/
HY-N19463 Dicatenarin
Dicatenarin is a caspase‑3 activator with growth‑inhibitory activity against human cancer cells. Dicatenarin increases caspase‑3 activity, induces intracellular ROS generation, and activates the mitochondrial‑mediated apoptotic pathway. Dicatenarin exerts growth‑inhibitory effects against a panel of human cancer cell lines. Dicatenarin can be used in research on pancreatic cancer, lung cancer, colon cancer, breast cancer, prostate cancer, and ovarian cancer.

Source: Penicillium pinophilum

Caspase   Reactive Oxygen Species (ROS)   Apoptosis  
Cancer  
/
HY-P991332 JAB-BX102
JAB-BX102 is a human monoclonal antibody (mAb) targeting NT5E/CD73. JAB-BX102 can be used in the study of cancers such as breast cancer, pancreatic cancer, and prostate cancer.

Species: Human

CD73  
Cancer  
/
HY-W248121 Pyrromethene 567
Pyrromethene 567 is a commercially available BODIPY dye with a photodynamic cytotoxicity IC50 of 6.8 ± 1.8 μM.Pyrromethene 567 shows cytoplasmic localization and limited cellular uptake in cancer cells.Pyrromethene 567 can be used for the research of lung cancer.
Fluorescent Dye  
Lung Cancer  
/
HY-13673S Goserelin-d10
Goserelin-d10 (ICI 118630-d10) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds  
Cancer   Metabolic or Endocrine Disease  
/
HY-P990252 Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma.

Species: Mouse

Notch   Interleukin Related   NF-κB   VEGFR   FGFR   NO Synthase  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N0976 1,11b-Dihydro-11b-hydroxymedicarpin
1,11b-Dihydro-11b-hydroxymedicarpin (11b-Hydroxy-11b,1-dihydromedicarpin) is a pterocarpan from Ononis viscosa subsp. breviflora is a Medicarpin derivative. Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways. Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Medicarpin down-regulates pro-inflammatory cytokines like TNF-α, IL-6 and IL-17A, while up-regulates anti-inflammatory cytokine IL-10 in arthritis (CIA) model of mice.
Interleukin Related   Wnt  
Inflammation or Immune System Disease  
/
HY-159846S Luvometinib-d
Luvometinib-d (FCN-159-d) is the deuterated-labeled Luvometinib (HY-159846). Luvometinib is an orally potent MEK1/2 inhibitor. Luvometinib selectively blocks the MAPK signaling pathway by forming a ternary complex with MEKase and ATP, thereby reducing the phosphorylation level of ERK. Luvometinib induces cell cycle arrest and apoptosis, and inhibits cancer cell proliferation. Luvometinib can be used in relevant research on various solid tumors including melanoma, non-small cell lung cancer, colon cancer, and acute myeloid leukemia.
Isotope-Labeled Compounds   MEK   p38 MAPK   Apoptosis  
Cancer  
/
HY-10585AS1 Valproic acid-d14 sodium
Valproic acid-d14 (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
Isotope-Labeled Compounds   HDAC   Autophagy   Mitophagy   HIV   Notch   Endogenous Metabolite  
/
HY-108692S Enterolactone-d6
Enterolactone-d6 is the deuterium labeled Enterolactone. Enterolactone is a bioactive phenolic metabolite known as a mammalian lignan derived from dietary lignans. Enterolactone has estrogenic properties and anti-breast cancer activity. Enterolactone is a radiosensitizer for human breast cancer cell lines through impaired DNA repair and increased apoptosis.
Isotope-Labeled Compounds   Apoptosis   Endogenous Metabolite  
/
HY-W1123936B DBCO-PEG1000-FA
DBCO-PEG1000-FA (DBCO-PEG1000-Folate) is a multifunctional bioconjugation reagent, which is a copolymer of DBCO and Folic acid (FA) (HY-16637) and can target folate receptors (FR). Folate receptors are highly overexpressed on the surface of many cancer cells (such as lung cancer, nasopharyngeal cancer, ovarian cancer, etc.), but exhibit extremely low expression levels in normal tissues. DBCO-PEG-FA can be used for click chemistry conjugation via its DBCO terminal, and thus applies to various bioconjugation and drug delivery applications.
Folate Receptor (FR)  
Cancer  
/
HY-W777317 Elacridar-d4(Major)
Elacridar-d4(Major) is the deuterium labeled Elacridar (HY-50879). Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer.
Isotope-Labeled Compounds   BCRP   P-glycoprotein  
/
HY-N13247 Ajuga Turkestanica Extract
Ajuga Turkestanica Extract is a muscle grass extract. Ajuga Turkestanica Extract can increase Notch and Wnt signaling in triceps brachii, and has potential skeletal muscle protection..
Notch   Wnt  
Metabolic or Endocrine Disease  
/
HY-P992107 Dulpatatug
Dulpatatug is a monoclonal antibody targeting ERBB2, which can be used for research on gastric cancer, breast cancer and non-small cell lung cancer.

Species: Human

EGFR  
Gastric Cancer  
/
HY-13673S2 Goserelin-d7 TFA
Goserelin-d7 (TFA) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer.
Isotope-Labeled Compounds   GnRH Receptor   Apoptosis  
Cancer   Metabolic or Endocrine Disease  
/
HY-N8890 Demissidine
Demissidine is an alkaloid that can be isolated from potato. Demissidine is a promising dual inhibitors against β- and γ-secretase proteins in silico.
Beta-secretase   γ-secretase  
/
HY-10585S4 Valproic acid-d4-1
Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
Isotope-Labeled Compounds   HDAC   Autophagy   Mitophagy   HIV   Notch   Endogenous Metabolite  
/
HY-116038 Kulinone
Kulinone is a triterpenoid anticancer agent. Kulinone induces cytotoxic effects in lung cancer and gastric cancer cells. Kulinone is isolated from the bark of Melia azedarach. Kulinone is applicable to research related to lung cancer and gastric cancer.
Biochemical Assay Reagents  
Lung Cancer   Gastric Cancer  
/
HY-P11078A LARLLT TFA
LARLLT TFA is an EGFR-binding peptide. LARLLT has the potential for research of EGFR overexpressing cancers, such as lung, ovarian and colorectal cancer.
EGFR  
Colorectal Cancer   Pancreatic Cancer   Ovarian Cancer   Hepatitis C Virus Infection  
/
HY-10585AR Valproic acid sodium (Standard)
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
Organoid   Reference Standards   HDAC   Autophagy   Mitophagy   HIV   Notch   Apoptosis   Endogenous Metabolite  
Infection   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Respiratory Disease   Small Cell Lung Cancer  
/
HY-145622 Mecbotamab vedotin
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162).
Antibody-Drug Conjugates (ADCs)   TAM Receptor  
Cancer  
/
HY-N11709 Theasaponin E1
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections.
Apoptosis   VEGFR   ATM/ATR   PTEN   Akt   mTOR   HIF/HIF Prolyl-Hydroxylase   NF-κB   Notch   Cholinesterase (ChE)   Amyloid-β   γ-secretase   Ferroptosis   Fungal  
Ovarian Cancer   Fungal Infection   Alzheimer's Disease   Obesity  
/
HY-W001603 Ethyl diethoxyacetate
Ethyl diethoxyacetate is a reagent used in organic synthesis. Ethyl diethoxyacetate has moderate antiproliferative effects on cervical cancer and liver cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-120234 Z-LLNle-CHO
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a γ-secretase inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia.
γ-secretase   Proteasome   Apoptosis  
Digestive System Disease   Breast Cancer   Leukemia/Lymphoma/Myeloma   Neurodegenerative Disease   Digestive System Inflammation  
/
HY-N2896 Arjunolic acid
Arjunolic acid is an orally active, multifunctional bioactive compound. Arjunolic acid exhibits free radical scavenging activity, as well as fungal and bacterial activities. Arjunolic acid induces apoptosis (Apoptosis) in various cancer cells. Arjunolic acid protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation. Arjunolic acid regulates pancreatic dysfunction in type 2 diabetic rats by blocking the activation of the TLR-4/MyD88 and canonical Wnt pathways. Arjunolic acid inhibits neuroinflammation and ameliorates depressive behaviors via the SIRT1/AMPK/Notch1 signaling pathway in microglia. Arjunolic acid improves Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling. Arjunolic acid suppresses osteosarcoma progression by inhibiting Wnt3a-mediated M2 polarization of macrophages. Arjunolic acid ameliorates diabetic retinopathy via the autophagy pathway regulated by AMPK/mTOR/HO-1. Arjunolic acid is applicable to research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction.
Free Radical Scavengers   Reactive Oxygen Species (ROS)   Apoptosis   Fungal   Bacterial   NF-κB   SOD   AMPK   mTOR   Notch   Toll-like Receptor (TLR)   Wnt   MyD88   Sirtuin  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Bacterial Infection   Fungal Infection   Depression   Digestive System Inflammation   Crohn's Disease  
/
HY-P990901 Aplitabart
Aplitabart (IGM-8444) is a pentameric IgM death receptor 5 (DR5) agonist antibody with a KD of 85 nM and an apparent affinity of 11 pM. Aplitabart induces DR5 multimerization, thereby triggering cancer cell apoptosis via the extrinsic apoptotic pathway apoptosis. Aplitabart is applicable to cancer-related research such as colorectal cancer and gastric cancer.

Species: Human

TNF Receptor   Apoptosis  
Colorectal Cancer   Gastric Cancer  
/
HY-W115609 N-Phenylbenzamide
N-Phenylbenzamide (N-Benzoylaniline) is a compound skeleton. N-Phenylbenzamide can be used for the researches of cancer and infection, such as enterovirus and cervical cancer.
Enterovirus   Biochemical Assay Reagents  
Infection  
/
HY-P991723 Varsetatug
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer.

Species: Human

ADC Antibodies   Transmembrane Glycoprotein  
Breast Cancer   Prostate Cancer   Ovarian Cancer  
/
HY-10585S1 Valproic acid-d6
Valproic acid-d6 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
HDAC   Autophagy   Mitophagy   HIV   Notch   Endogenous Metabolite  
/
HY-W008091S 5-Methylcytosine-d4
5-Methylcytosine-d4 is the deuterium labeled 5-Methylcytosine (HY-W008091). 5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma.
DNA/RNA Synthesis   Endogenous Metabolite   Isotope-Labeled Compounds  
/
HY-P99925 Enoticumab
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively.

Species: Human

Notch  
Cancer   Metabolic or Endocrine Disease  
/
HY-N1510 Kaempferol 3-O-gentiobioside
Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a Ka value of 57 µM against human NOTCH1 and an IC50 value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the TGF-β/ALK5/Smad signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma. It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer.
Glycosidase   Notch   Toll-like Receptor (TLR)   NF-κB   Mucin   Reactive Oxygen Species (ROS)   Bacterial   TGF-beta/Smad   Anaplastic lymphoma kinase (ALK)  
Breast Cancer   Gastric Cancer   Ovarian Cancer   Autoimmune Disease   Staphylococcus Aureus Infection   Allergic Asthma  
/
HY-10585S2 Valproic acid-d15
Valproic acid-d15 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
HDAC   Autophagy   Mitophagy   HIV   Notch   Endogenous Metabolite  
/
HY-76562 Methyl 6-bromopicolinate
Methyl 6-bromopicolinate is a synthetic intermediate used in the preparation of γ-secretase inhibitor library scaffolds.
Biochemical Assay Reagents  
/
HY-114491 Rineterkib
Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
ERK   Raf  
/
HY-P1940 Maculosin
Maculosin (Cyclo (Tyr-Pro)) is a host-specific phytotoxin for spotted knapweed from Alternaria alternata. Maculosin is a quorum-sensing molecule involved in cell-cell communication. Maculosin also acts as a signaling molecule regulating virulence gene expression. Maculosin shows antimicrobial, antifungal, antioxidant and anti-cancer properties.Maculosin (Cyclo (Tyr-Pro)) is a host-specific phytotoxin for spotted knapweed from Alternaria alternata. Maculosin is a quorum-sensing molecule involved in cell-cell communication. Maculosin also acts as a signaling molecule regulating virulence gene expression. Maculosin shows antimicrobial, antifungal, antioxidant and anti-cancer properties.

Source: Streptomyces sp. KTM18

Endogenous Metabolite   Free Radical Scavengers   Bacterial   Fungal  
Cancer   Bacterial Infection  
/
HY-W020952 Palladium(Ⅱ) acetylacetonate
Palladium(II) acetylacetonate is a metal-organic complex. Palladium(II) acetylacetonate upregulates the expression of GRP78, ATF-4, XBP-1, CHOP, and phosphorylated c-Jun. Palladium(II) acetylacetonate induces Apoptosis. Palladium(II) acetylacetonate has anticancer effects against non-small cell lung cancer, gastric cancer, leukemia, and cervical cancer.
Biochemical Assay Reagents   HSP   Eukaryotic Initiation Factor (eIF)   IRE1   JNK   Apoptosis  
Cancer  
/
HY-P990717 Brenetafusp
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects CD3+ T cells to kill PRAME+ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer.

Species: Human

CD3  
Cancer  
/
HY-78216 2-Thiooxamic acid ethyl ester
2-Thiooxamic acid ethyl ester is an organic compound containing thiocarbonyl and ethyl ester groups. 2-Thiooxamic acid ethyl ester can be used in the study of cancer (such as chronic myeloid leukemia, breast cancer, etc.) .
Biochemical Assay Reagents  
Cancer  
/
HY-P99258 Brontictuzumab
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.

Species: Human

Notch  
Leukemia/Lymphoma/Myeloma   Metastatic Colorectal Cancer  
/
HY-13027G DAPT (GMP)
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active γ-secretase inhibitor.
γ-secretase  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-33287 2-Bromothiazole-5-carboxylic acid
2-Bromothiazole-5-carboxylic acid is a starting compound in the synthesis of active compounds. 2-Bromothiazole-5-carboxylic acid can be used in the synthesis of NAMPT/HDAC inhibitors. 2-Bromothiazole-5-carboxylic acid can be used in the research of colon cancer, lung cancer, and liver cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-P99320 Tarextumab
Tarextumab (OMP-59R5) is a cross-reactive, fully human IgG2 antibody that selectively inhibits Notch2 and Notch3 signaling. Tarextumab demonstrates broad-spectrum antitumor efficacy in xenograft models of epithelial tumors. Tarextumab can be used for the study of pancreatic cancer.

Species: Human

Notch  
Triple-Negative Breast Cancer  
/
HY-156002 LUNA18
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer.
Ras   ERK  
Respiratory Disease   Non-Small Cell Lung Cancer  
/
HY-P71043 SNCG Protein, Human
SNCG proteins help maintain the integrity of neurofilament networks and may influence axonal structure during development and adulthood. In vitro, it enhances the sensitivity of neurofilament-H to calcium-dependent proteases. SNCG Protein, Human is the recombinant human-derived SNCG protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

/
HY-P71928 TFF1 Protein, Human
TFF1 protein functions as a mucous gel stabilizer, vital for fortifying the gastrointestinal mucosa against noxious agents. It contributes to the mucous layer's integrity, providing a crucial physical barrier for the gastrointestinal tract, safeguarding it from potential harm. TFF1's stabilizing role emphasizes its significance in preserving the mucosal barrier, essential for overall gastrointestinal health and protection. TFF1 Protein, Human is the recombinant human-derived TFF1 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Cytokines and Growth Factors

/
HY-P703091 BRCA1 Protein, Human
BRCA1 Protein, Human is the recombinant human-derived BRCA1, expressed by E. coli, with tag free labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Transferases (EC 2)

/
HY-P7677 BIN2 Protein, Human (His)
BIN2 Protein, Human (His) is a recombinant human bridging integrator 2 (BIN2) with a His tag.

Species: Human; Source: E. coli

/
HY-P72054 RCVRN Protein, Human (sf9, His-Myc)
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (sf9, His-Myc) is the recombinant human-derived RCVRN protein, expressed by sf9 insect cells , with N-10*His, C-Myc labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P71778 RCVRN Protein, Human (P.pastoris, His)
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (P.pastoris, His) is the recombinant human-derived RCVRN protein, expressed by P. pastoris , with N-His labeled tag.

Species: Human; Source: P. pastoris

/
HY-P76849 CSAG1 Protein, Human (HEK293, Fc)
CSAG1 Protein is a potential key player in maintaining centrosome integrity during mitosis, impacting chromosome segregation. The mechanisms underlying its contribution to centrosome stability require elucidation. Its putative involvement highlights significance in mitosis-related cellular events. Further research is essential to unravel precise details of CSAG1's function and its implications for centrosome integrity during mitosis. CSAG1 Protein, Human (HEK293, Fc) is the recombinant human-derived CSAG1 protein, expressed by HEK293 , with N-hFc labeled tag.

Species: Human; Source: HEK293

/
HY-P73700 PRAC Protein, Human (His-SUMO)
PRAC Protein exhibits high expression in the prostate, rectum, and distal colon, with weaker expression in the bladder. Its prominence in prostate cancer cell lines suggests a potential link to prostate cancer pathology. The tissue-specific expression emphasizes PRAC Protein's potential roles in normal physiological processes and cancer contexts. PRAC Protein, Human (His-SUMO) is the recombinant human-derived PRAC protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Species: Human; Source: E. coli

/
HY-P702211 APH1A Protein, Human (Cell-Free, His, SUMO)
The APH1A protein is a noncatalytic subunit of the γ-secretase complex and is essential for the assembly of this endoprotease. The γ-secretase complex, including presenilin homodimer, nicastrin, APH1A, and PSENEN/PEN2, catalyzes the cleavage of intramembrane proteins such as Notch and APP. APH1A Protein, Human (Cell-Free, His, SUMO) is the recombinant human-derived APH1A protein, expressed by E. coli Cell-free , with N-6*His, N-SUMO labeled tag.

Species: Human; Source: E. coli Cell-free

/
HY-P703092 BRCA2 Protein, Human (HEK293, His, Strep, Flag)
BRCA2 Protein, Human (HEK293, His, Strep, Flag) is the recombinant human-derived BRCA2, expressed by HEK293, with Strep, His, Flag labeled tag.

Species: Human; Source: HEK293

/
HY-P86790 BRCA2 Antibody (YA6483)
BRCA2 Antibody (YA6483) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRCA2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86827 CTAG1B Antibody (YA6520)
CTAG1B Antibody (YA6520) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CTAG1B.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811127 Recoverin Antibody
Recoverin Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Recoverin.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P80305 RBPJK Antibody (YA099)
RBPJK Antibody (YA099) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RBPJK.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811296 CTAG1B Antibody
CTAG1B Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CTAG1B.

Host: Rabbit; Reactivity: Human

Polyclonal Antibodies Primary Antibodies

/
HY-P83052 CEP55 Antibody (YA2797)
CEP55 Antibody (YA2797) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEP55.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83052A CEP55 Antibody (YA2797)(PBS only)
CEP55 Antibody (YA2797) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEP55.

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86253 NABC1 Antibody (YA5945)
NABC1 Antibody (YA5945) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NABC1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86753 MUC16 Antibody (YA6445)
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86753A MUC16 Antibody (YA6445)(PBS only)
MUC16 Antibody (YA6445) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to MUC16.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P87366 BLCAP Antibody (YA7049)
BLCAP Antibody (YA7049) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to BLCAP.

Host: Mouse; Reactivity: Human, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-K6101 Human Breast Cancer Organoid Kit

MCE Human Breast Cancer Organoid Kit contains Breast Cancer Organoid Basal Medium A, Breast Cancer Organoid Supplement B (50×), Breast Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human breast cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6103 Human Small Cell Lung Cancer Organoid Kit

MCE Human Small Cell Lung Cancer Organoid Kit contains Small Cell Lung Cancer Organoid Basal Medium A, Small Cell Lung Cancer Organoid Supplement B (50×),Small Cell Lung Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human small cell lung cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6104 Human Colorectal Cancer Organoid Kit

MCE Human Colorectal Cancer Organoid Kit contains Colorectal Cancer Organoid Basal Medium A, Colorectal Cancer Organoid Supplement B (50×), Colorectal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human colorectal cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6107 Human Cervical Cancer Organoid Kit

MCE Human Cervical cancer Organoid Kit contains Cervical cancer Organoid Basal Medium A, Cervical cancer Organoid Supplement B (50×), Cervical cancer Organoid Supplement C (250×). This product can be used to efficiently construct human cervical cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6108 Human Esophageal Cancer Organoid Kit

MCE Human Esophageal Cancer Organoid Kit contains Esophageal Cancer Organoid Basal Medium A, Esophageal Cancer Organoid Supplement B (50×), Esophageal Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human esophageal cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6109 Human Endometrial Cancer Organoid Kit

MCE Human Endometrial Cancer Organoid Kit contains Endometrial Cancer Organoid Basal Medium A, Endometrial Cancer Organoid Supplement B (50×), Endometrial Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human endometrial cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6110 Human Pancreatic Cancer Organoid Kit

MCE Human Pancreatic Cancer Organoid Kit contains Pancreatic Cancer Organoid Basal Medium A, Pancreatic Cancer Organoid Supplement B (50×), Pancreatic Cancer Organoid Supplement C (250×). This product can be used to efficiently construct human pancreatic cancer organoid.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6123 Human Ovarian Cancer Organoid Kit

MCE Human Ovarian Cancer Organoid Kit includes a basic culture medium for ovarian cancer organoids, as well as culture supplements, and is designed for the effective construction of human ovarian cancer organoids.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/
HY-K6126 Human Kidney Cancer Organoid Kit

MCE Human Kidney Cancer Organoid Kit includes a basic culture medium for Kidney Cancer organoids, as well as culture supplements, and is designed for the effective construction of human Kidney Cancer organoids.

Cell Biology 3D Cell Culture Tumor Organoid Culture Medium

/

Keywords

Notch signaling | multimodal signaling | cell-cell communication | developmental biology | NICD | RBPJ | gamma-secretase | cancer